3F8 monoclonal antibody treatment of patients with stage 4 neuroblastoma: a phase II study.

  • Authors:
    • N K Cheung
    • B H Kushner
    • S D Yeh
    • S M Larson
  • View Affiliations

  • Published online on: Monday, June 1, 1998
  • Pages: 1299-1605
  • DOI: 10.3892/ijo.12.6.1299

Abstract

3F8 is an IgG3 murine monoclonal antibody directed against the ganglioside GD2. In a phase II study, 3F8 was administered i.v. to 16 patients (pts) who had stage 4 neuroblastoma. Response was seen in bony lesions (2 of 7 pts) and marrow (3 of 8 pts). Acute toxicities of pain, fever, urticaria, hypertension, hypotension and anaphylactoid reactions were self-limited and manageable. Three pts are long-term survivors between 79-130+ months after 3F8 treatment without additional systemic therapy and no delayed neurological complications. The potential benefits of 3F8 when added to chemoradio-therapy warrant further investigation.
Journal Cover

June 1998
Volume 12 Issue 6

Print ISSN: 1019-6439
Online ISSN:1791-2423

2013 Impact Factor: 2.773
Ranked #30/202 Oncology
(total number of cites)

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Cheung, N., Kushner, B., Yeh, S., & Larson, S. (1998). 3F8 monoclonal antibody treatment of patients with stage 4 neuroblastoma: a phase II study.. International Journal of Oncology, 12(6), 1299-1605.
MLA
Cheung, Kushner, Yeh, and S M Larson. "3F8 monoclonal antibody treatment of patients with stage 4 neuroblastoma: a phase II study.." International Journal of Oncology International Journal of Oncology 12.6 (1998): 1299-1605.
Chicago
Cheung, Kushner, Yeh, and S M Larson. "3F8 monoclonal antibody treatment of patients with stage 4 neuroblastoma: a phase II study.." International Journal of Oncology International Journal of Oncology 12 no. 6 (1998): 1299-1605.